
KISQALI® (ribociclib) NOW FDA APPROVED for early breast cancer

Dear CHOP Member:

I am reaching out to you to share the news regarding a new indication approved for KISQALI® (ribociclib) tablets on September 17, 2024.

KISQALI is NOW APPROVED as a treatment option for patients with HR+/HER2- early breast cancer (eBC) and available today.

I would like to share clinical information associated with KISQALI in eBC. Could you please share availability and I'll do my best to make the arrangements.

Please [click here](#) for full Prescribing Information.

Sincerely,

Jeff

Jeff Osmundson
Regional Markets, US Market Access
Novartis Pharmaceuticals
Jeffrey.osmundson@novartis.com
913-484-5444 (Mobile)

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080
11258011

© 2024 Novartis

9/24

FA-